Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them using RNA interference technology. The company’s approach centers on the RNA induced pathway, wherein small interfering RNA triggers are loaded into the RNA induced silencing complex to degrade messenger RNA and halt production of disease associated proteins. Arrowhead employs a broad portfolio of RNA chemistries and delivery systems, including its proprietary Targeted RNAi Molecule TIM platform, to enable tissue specific targeting beyond the liver. As of the filing, the company had 18 drug candidates in clinical trials ranging from Phase 1 to Phase 3 and a robust discovery stage pipeline capable of yielding multiple new clinical candidates each year. It also achieved its first commercial launch with the FDA approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome in 2025.

Revenue is generated principally from the sale of its FDA approved product REDEMPLO, which is marketed as an adjunct to diet for reducing triglycerides in adults with Familial Chylomicronemia Syndrome. In addition, the company receives upfront payments, milestone payments, and royalties under its numerous licensing and collaboration agreements with partners such as Sarepta Therapeutics, Amgen, Takeda, GSK, and Novartis. These collaborations often involve the co development of RNAi therapeutics for indications that the partners intend to commercialize, while Arrowhead retains rights to receive financial consideration upon achievement of preclinical, clinical, and commercial milestones. The firm also pursues revenue from potential future sales of its pipeline candidates, including those targeting severe hypertriglyceridemia, hepatocellular diseases, and cardiovascular disorders, should they obtain regulatory approval.

Arrowhead occupies a competitive niche within the broader nucleic acid therapeutics sector, distinguished by its proprietary TIM platform that enables delivery of siRNA to a variety of extrahepatic cell types, a capability that many peers limited to hepatocyte directed approaches lack. The company’s deep pipeline, with 18 clinical stage candidates and a continuous flow of discovery stage molecules, provides a diversified risk profile compared to rivals that rely on one or two lead assets. Strategic alliances with large pharmaceutical companies including Sarepta, Amgen, Takeda, GSK, and Novartis only supply non dilutive funding but also validate Arrowhead’s technology and expand its reach into therapeutic areas such as muscle disorders, cardiometabolic disease, and central nervous system indications. While competitors such as Alnylam Pharmaceuticals and Dicerna Pharmaceuticals focus primarily on liver targeted RNAi, Arrowhead’s ability to target tissues like the lung, brain, muscle, and kidney offers a differentiated advantage in addressing underserved markets.

The company's customers consist primarily of patients diagnosed with rare genetic disorders that arise from overproduction of specific proteins, such as Familial Chylomicronemia Syndrome and severe hypertriglyceridemia, for whom its approved and pipeline therapies aim to reduce disease causing protein levels. Arrowhead also serves a set of biopharmaceutical collaborators that license its RNAi technology or co develop candidates, including Sarepta Therapeutics, which focuses on neuromuscular and central nervous system disorders; Amgen, which advances cardiovascular programs; Takeda, which develops treatments for alpha 1 antitrypsin deficiency; GSK, which pursues programs in metabolic associated steatohepatitis and hepatitis B; and Novartis, which explores neurodegenerative targets such as alpha synuclein. These partnerships provide Arrowhead with access to broader patient populations while the collaborators gain the ability to commercialize the resulting therapies.